“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

Active surveillance is effective for low-risk prostate cancer, with low metastasis and mortality rates over 10 years. The study underscores the need for improved risk stratification to minimize ...

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

Darolutamide's structure limits blood-brain barrier penetration, reducing central nervous system side effects and improving safety. It effectively delays metastasis and prolongs survival in ...

Urologists need oncologists to provide systemic therapy insights and manage immune-related adverse events in combination therapy. Oncologists rely on urologists for expertise in local disease ...

UGN-102's NDA acceptance marks a potential first FDA-approved treatment for LG-IR-NMIBC, with a PDUFA date of June 13, 2025. The phase 3 ENVISION trial demonstrated a 79.6% complete response rate at 3 ...

The NRG-GU011 trial evaluates relugolix plus SBRT versus SBRT alone in men with PSA recurrence and PSMA-PET-detected metastases. The study addresses whether targeted radiation can delay hormone ...

Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential ...

PSMA-PET imaging enables molecular-level detection of prostate cancer cells, often before CT or MRI abnormalities are visible. Sensitivity of PSMA-PET/CT in recurrent prostate cancer can reach 97% ...

Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor ...

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by ...